<DOC>
	<DOCNO>NCT00663260</DOCNO>
	<brief_summary>The purpose study determine whether dapagliflozin effective treatment type 2 diabetes subject poor blood sugar control moderate renal impairment</brief_summary>
	<brief_title>Glycemic Efficacy Renal Safety Study Dapagliflozin Subjects With Type 2 Diabetes Mellitus Moderate Renal Impairment</brief_title>
	<detailed_description>All eligible subject receive single-blind placebo medication 1-week lead-in period prior randomization . All arm may include addition open label medication describe ( need rescue base protocol specific criterion ) . Rescue medication define addition approve , appropriate antihyperglycemic agent , except metformin , use accord conventional standard care , treat hyperglycemia , may therefore allow subject remain trial</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Males female , â‰¥18 year old , type 2 diabetes inadequate glycemic control Clinical diagnosis moderate renal impairment AST /or ALT &gt; 3.0 time upper limit normal Serum total bilirubin &gt; 1.5 time ULN Symptoms severely uncontrolled diabetes Currently unstable serious cardiovascular , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>